Babesia microti: Difference between revisions
From IDWiki
Babesia microti
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations") |
m (→) |
||
(6 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
==Background== |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
*Has been found in Canada as of 2013, with several case reports from Manitoba and on case report of [[Babesia duncani]] infection in souther Ontario[[CiteRef::yang2021ba]] |
|||
*Typically takes 36 hours or longer of tick attachment to be transmitted to human host |
|||
====Other Species==== |
|||
⚫ | |||
⚫ | |||
⚫ | |||
== Life Cycle == |
|||
⚫ | |||
⚫ | |||
[[File:Babesia_LifeCycle_1.gif|Babesia life cycle]] |
|||
⚫ | |||
⚫ | |||
**Diagnosis can be delayed |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
=== Prognosis and Complications === |
|||
⚫ | |||
* Can have delayed diagnosis |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
=== Transplacentally-acquired neonatal infection === |
|||
*More severe illness in patients with [[asplenia]], [[X-linked agammaglobulinemia]], [[malignancy]], [[HIV]] with low CD4 count, [[TNF-α inhibitors]], and immunosuppression for transplantation, [[B-cell lymphoma]], or autoimmune disorders |
|||
===Congenital Infection=== |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
=== Other ''Babesia'' species === |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
* Mild: atovaquone plus azithromycin |
|||
⚫ | |||
* Severe: clindamycine plus quinine, ± RBC exchange transfusion |
|||
*'''Mild''': [[Is treated by::atovaquone]] 750 mg PO q12h plus [[Is treated by::azithromycin]] 500-1000 mg PO once followed by 250-500 mg PO daily for 7 to 10 days |
|||
⚫ | |||
*'''Severe''': [[Is treated by::clindamycin]] 300-600 mg IV q6h or 600 mg PO q8h plus [[Is treated by::quinine]] 650 mg PO q6-8h |
|||
⚫ | |||
**± RBC exchange transfusion if parasitemia ≥10%, severe hemolysis, or pulmonary, renal, or hepatic failure |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
{{DISPLAYTITLE:''Babesia microti''}} |
{{DISPLAYTITLE:''Babesia microti''}} |
||
[[Category:Vector-borne infections]] |
[[Category:Vector-borne infections]] |
||
[[Category: |
[[Category:Haemosporida]] |
Latest revision as of 15:53, 2 May 2024
Background
- Causes babesiosis
Microbiology
- Tickborne protozoa
- Different species of Babesia exist
- Seen as Maltese cross on blood smear
Epidemiology
- Tickborne by Ixodes scapularis
- Reservoir is white-footed mice
- Can be transmitted by blood transfusion and, rarely, transplacentally (5 cases)
- More common in the northeastern US, including Connecticut, Massachusetts, Minnesota, New Jersey, New York, Rhode Island, and Wisconsin
- Highly endemic in Nantucket, Martha's Vineyard, the Elizabeth Islands, Block Island, Shelter Island, eastern Long Island, an Fire Island
- Has been found in Canada as of 2013, with several case reports from Manitoba and on case report of Babesia duncani infection in souther Ontario1
- Typically takes 36 hours or longer of tick attachment to be transmitted to human host
Other Species
- B. duncani and B. duncani-type organisms are present in the Pacific Coast
- B. divergens in Europe; rarely B. venatorum
Clinical Manifestations
- Incubation period 1 to 6 weeks
- Diagnosis can be delayed
- There are some cases of asymptomatic parasitemia
- May experience recrudescence after immunosuppression
- Symptoms include fatigue, weakness, and malaise, followed by fever and chills, arthralgias, or nausea
- Fever may be intermittent or persistent, and can be high
- Can also cause nuchal rigidity, sore throat, dyspnea, weight loss, vomiting, diarrhea, and dark urine
- Occasionally causes emotional lability, depression, hyperesthesia, photophobia, conjunctival injection, abdominal pain, petechiae, and ecchymoses
- May have erythema chronicum migrans rash in cases of coinfection
- Bloodwork shows anemia, jaundice, and other evidence of hemolysis, often with positive direct antiglobulin test
- Also thrombocytopenia and liver enzyme abnormalities
- If neutropenia, suggests coinfection with anaplasmosis
Prognosis and Complications
- 40% develop complications, including ARDS, DIC, CHF, coma, AKI, splenic rupture
- More severe illness in patients with asplenia, X-linked agammaglobulinemia, malignancy, HIV with low CD4 count, TNF-α inhibitors, and immunosuppression for transplantation, B-cell lymphoma, or autoimmune disorders
Congenital Infection
- Five cases
- Symptom onset around 3 to 6 weeks
- Parasitemia 2-15% on diagnosis
Other Babesia species
- B. divergens usually in asplenic patients, causing fulminant disease
Diagnosis
- Parasites visualized on blood film, with parasitemia from 1 to 20% but as high as 85% in splenectomized patients
Management
- Asymptomatic parasitemia: no treatment necessary unless immunocompromised or persists for longer than 3 months
- Mild: atovaquone 750 mg PO q12h plus azithromycin 500-1000 mg PO once followed by 250-500 mg PO daily for 7 to 10 days
- Severe: clindamycin 300-600 mg IV q6h or 600 mg PO q8h plus quinine 650 mg PO q6-8h
- ± RBC exchange transfusion if parasitemia ≥10%, severe hemolysis, or pulmonary, renal, or hepatic failure
- B. divergens: RBC exchange transfusion plus clindamycin plus quinine
- Duration
- 7 to 10 days for most
- Can relapse when immunocompromised, so these patients need 6+ weeks including 2+ weeks without parasitemia
References
- ^ Jiayu Yang, Catherine Smith, Anthony Battad. Babesia microti acquired in Canada. Canadian Medical Association Journal. 2021;193(31):E1213-E1217. doi:10.1503/cmaj.201983.